39 Questions
What is the main purpose of Preamble Guidelines?
Assist health professionals in recommending the best diagnostic or therapeutic approach
Who are the Guidelines intended for?
Health professionals
What is the responsibility of health professionals according to the text?
To consult with patients or caregivers when making decisions
Where can ESC Guidelines be freely accessed?
On the ESC website for free
What is the responsibility of health professionals regarding rules verification?
Verify and follow the rules diligently
What specific recommendations can be found in Table 4 of the ESC Guidelines?
Prevention of heart failure in patients with type 2 diabetes mellitus and chronic kidney disease
Where can one find the ESC Guidelines referenced in the text?
'ESC Guidelines' section on the ESC website
What is the role of health professionals in making decisions according to the ESC Guidelines?
To make appropriate and accurate decisions based on patient's condition and guidelines
What is required before translating or reproducing any part of the document?
Submission of a written request to Oxford University Press
Where can the declarations of interest of experts involved in the development of the Focused Update be found?
On the ESC website
What entity is authorized to handle permissions for translating or reproducing the document?
Oxford University Press
Where can supplementary documents, including evidence tables, be accessed?
European Heart Journal online
What is the first step required to obtain permission for translating or reproducing the document?
Submit a written request to ESC
Who is responsible for publishing supplementary documents that include evidence tables?
European Heart Journal
How are declarations of interest from experts involved in the Focused Update made public?
In a report published online
What must experts involved in the development of the Focused Update do regarding their declarations of interest?
Submit them for compilation in a report
Who reviews the ESC Guidelines and Focused Updates before publication?
CPG Committee and external experts
What is the final step before the publication of finalized ESC Guidelines and Focused Updates?
Sign off by the CPG Committee
What caution does the ESC provide to readers in relation to the technical language used in the Guidelines and Focused Updates?
It might be misinterpreted
Which group of experts may be involved in the development of a Focused Update?
Members from relevant ESC Subspecialty Communities
In what circumstance might off-label use of medication be presented in an ESC Focused Update?
If there is compelling evidence for its appropriate use
What type of evidence informs the development of an ESC Focused Update?
Scientific and medical knowledge
Who signs off on the Guidelines and Focused Updates for publication in the European Heart Journal?
CPG Committee members
What is included in a Focused Update to summarize study findings?
Tables of evidence
What is the LVEF range for heart failure with reduced ejection fraction?
Less than or equal to 40%
Which type of heart failure is associated with mildly reduced ejection fraction?
HFmrEF
What is a key characteristic of heart failure with preserved ejection fraction (HFpEF)?
LVEF ≥50%
Which parameter suggests the likelihood of heart failure with preserved ejection fraction?
Increased left atrial size
In heart failure, signs may not be present in the early stages, especially in which type?
HFpEF
What does the abbreviation 'LV' stand for in the context of heart failure?
Left Ventricle
'HF' stands for which term in relation to heart conditions?
Heart Failure
What was the outcome of the STRONG-HF trial in terms of HF hospitalizations?
There was a significant reduction in HF hospitalizations.
Who was the specific patient population studied in the STRONG-HF trial?
Patients with elevated NT-proBNP concentrations and a >10% decrease in concentration between screening and randomization.
What treatment was recommended based on the STRONG-HF trial results?
A combination of multiple treatments including empagliflozin or dapagliflozin.
What were the inclusion criteria for patients in the DAPA-CKD trial?
Patients with a urinary albumin-to-creatinine ratio ≥200 mg/g and an eGFR of 25–75 mL/min/1.73 m2.
What percentage of patients enrolled in the DAPA-CKD trial had a history of HF?
11%
What was the primary outcome measured in the DAPA-CKD trial?
Composite of sustained decline in eGFR of ≥50%, end-stage kidney disease, or kidney-related or CV death.
In which patient population did dapagliflozin show a 39% reduction compared to placebo in the DAPA-CKD trial?
Diabetic and non-diabetic patients with a urinary albumin-to-creatinine ratio ≥200 mg/g and an eGFR of 25–75 mL/min/1.73 m2.
What was the HR (Hazard Ratio) for the primary outcome in the DAPA-CKD trial comparing dapagliflozin to placebo?
0.61
Learn about the copyright permissions for the European Heart Journal document and how to obtain permission for translation or reproduction. Find out the process and contact information for seeking authorization from Oxford University Press.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
